InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device
InVera Medical secured FDA 510(k) clearance for its InVera Infusion Device, a 5Fr catheter with a helical coil designed to improve sclerotherapy delivery for chronic venous disease (CVD). The non‑thermal, minimally invasive tool prepares the vein wall mechanically, allowing a single local‑anesthetic injection and faster patient recovery. Over 120 million adults in the U.S. and Europe live with CVD, yet only about 1% receive treatment annually. InVera also holds CE Mark approval, positioning the device for limited rollout in select U.S. and European centers this year.
Diagnostics Lag Is Holding Back New Therapies, Says Study
A new UCSF analysis published in Science warns that diagnostic development is lagging behind therapeutic breakthroughs because of regulatory and reimbursement gaps. The authors highlight that nearly half of the world’s population—about 47%—has limited or no access to essential tests,...
Blocking 15-PGDH Reverses Age‑Related Cartilage Loss
As a medical school professor, I was taught that lost cartilage is gone forever. Stanford just proved that wrong. Researchers discovered that blocking a single protein (15-PGDH) -- which rises as we age -- can actually REGROW joint cartilage in aging mice. The...
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
DualityBio announced that China’s National Medical Products Administration has accepted its Biologics License Application for trastuzumab pamirtecan (T‑Pam), an investigational antibody‑drug conjugate targeting HER2‑positive metastatic breast cancer. The submission is backed by interim data from the pivotal Phase III DB‑1303‑O‑3001 trial,...
FDA Probes Abortion Pill Anew After Court Keeps Mail Access Alive
The FDA announced a renewed, accelerated safety study of the abortion pill mifepristone, aiming to complete the review faster than typical academic timelines. The move follows a Louisiana federal judge’s decision to temporarily allow the drug’s distribution by mail while...
New GLP‑3 Drug Reta May Target Fat, Spark Hunger
Like it or not, GLP-1-based weight loss drugs are here to stay. 1/2) What's more, people are experimenting with newer evolutions, like "reta" (retatrutide/GLP-3). As an MD PhD & metabolism scientist, I decided to start my own experiment to help answer...
Regeneration Depends on Environment, Oxygen, and Epigenetics
Awakening latent regeneration in mammals “regeneration is not simply a fixed genetic trait but rather a state that is dependent on the extracellular environment, oxygen sensing, and epigenetics.” https://t.co/HtTXENUEur
Novo's Double Departures: As GLP-1 Luminary Retires, an Obesity Leader Goes to Boehringer Ingelheim
Novo Nordisk announced two high‑profile departures this week. Lotte Bjerre Knudsen, a veteran who helped launch the company’s breakthrough GLP‑1 therapies, is retiring after more than two decades. At the same time, the head of Novo’s obesity unit has accepted a...
Why Experts Say Now Is the Time to Vaccinate US Dairy Cattle Against Bird Flu
The H5N1 bird‑flu virus, which devastated U.S. poultry in 2022, has jumped to dairy cattle, affecting over 1,000 herds in 19 states and generating an estimated $14 billion economic hit, including $4 billion in dairy losses. Researchers argue that vaccinating cattle could...
Advancing Single-Cell Transcriptomics Into the Mainstream of Biomedical Research
Single‑cell transcriptomics is transitioning from a niche method to a core biomedical tool, offering cell‑level gene‑expression detail that fuels advances in cancer, immunology and cell‑therapy research. Manual library‑preparation steps limit throughput to about 24 samples per day, creating bottlenecks for...
Chinese Trial Backs Base-Editing Drug for Thalassaemia
A Chinese investigator‑led trial of CorrectSequence Therapeutics' ex vivo base‑editing drug CS‑101 showed that all five patients with transfusion‑dependent beta‑thalassaemia became transfusion‑independent after a single infusion, with an average cessation time of 16 days and sustained hemoglobin gains over three months....
Sobi Reports Health Canada Approval of Empaveli for C3G and Primary IC-MPGN
Health Canada has granted approval for Empaveli (pegcetacoplan) to treat patients aged 12 and older with C3 glomerulopathy (C3G) or primary immune‑complex membranoproliferative glomerulonephritis (IC‑MPGN). The decision follows the Phase III VALIANT trial, which demonstrated a 68% reduction in proteinuria, stabilization...
Meal Delivery and Phone Counseling Cut Veteran Blood Pressure in New Trial
A randomized trial led by University of Michigan and VA Ann Arbor found that two weeks of home‑delivered DASH‑SRD meals followed by five phone‑based dietitian sessions reduced blood pressure in middle‑aged and older veterans with hypertension and obesity. The study,...
CNN Debuts Kara Swisher’s Six‑Part Docuseries on Extending Human Lifespan
CNN launched a six‑part documentary series titled “Kara Swisher Wants to Live Forever,” premiering Saturday, April 11, 2026. Hosted by veteran tech journalist Kara Swisher, the series probes the science, technology and commercial forces shaping human longevity. The debut places...
NPPA Gene Therapy to Encourage Greater Regeneration Following Heart Attack
Researchers at Columbia Engineering have engineered an RNA‑lipid nanoparticle that programs skeletal muscle to secrete a pro‑ANP precursor, which the heart‑specific enzyme Corin converts into active atrial natriuretic peptide. This two‑phase gene‑therapy bypasses the need for direct cardiac drug delivery,...
Study Identifies Brain Region Driving Hypertension, Offers New Biohacking Target
Scientists from the University of São Paulo and the University of Auckland discovered that the lateral parafacial (pFL) brain region can trigger hypertension in rats. Inactivating this region returned blood pressure to normal, suggesting a novel therapeutic target for biohackers...
FDA Pulls GSK's Wellcovorin Autism Approval After Company Request
The U.S. Food and Drug Administration has withdrawn its approval of GlaxoSmithKline's Wellcovorin, a branded leucovorin marketed for autism, after GSK formally requested the action. The reversal, noted in the Federal Register, underscores the unusual nature of pulling a drug...
ArkBio Starts First‑Cohort Dosing of Long‑Acting Antiviral AK0406 in Australian Phase I Trial
Shanghai Ark Biopharmaceutical announced that the first cohort of healthy volunteers has been dosed in a Phase I trial of AK0406, its long‑acting antiviral drug‑Fc conjugate, in Australia. The trial will assess safety, tolerability and pharmacokinetics, and could pave the...
Decoding ORR: What RECIST v1.1 Means for Investors
Investors will often see ORR quoted or displayed for oncology clinical trial results for solid tumors Here's what the CRs/PRs/SDs mean at a high level These are assessed on scans I'm using RECIST v1.1 definitions #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/eZb86TcoLL
Telix Pharma Shares Jump Up to 10% After FDA Accepts NDA for Brain Cancer Imaging Agent TLX101‑Px
Telix Pharmaceuticals saw its shares climb as much as 10% in U.S. trading after the FDA accepted its resubmitted New Drug Application for TLX101‑Px, an investigational PET imaging agent for glioma. The agency set a PDUFA goal date of Sept. 11,...
Cleveland Clinic Catalyzer Program Awards $250K to Quantum Startups
Cleveland Clinic’s Quantum Innovation Catalyzer Program will award up to $250,000, matched with in‑kind resources, to three startups applying quantum computing to health challenges. The selected firms—EntangleBio, Polaris Quantum Biotech, and Singularity Quantum—gain access to IBM’s Quantum System One, the...
Surface‑Engineered Primer Immobilization Enables Simplified and Affordable Nucleic‑Acid Capture for Molecular Diagnostics in Sub‑Saharan Africa
A study introduces a silica‑free nucleic‑acid capture method using polycarbonate surfaces modified with acetone‑UV pretreatment and branched polyethyleneimine linkers. The treatment doubles surface carboxyl groups, and BPEI chemistry attaches about 2.6 times more primers than conventional ethylenediamine links. Fluorescence assays confirm...
Molecular Farming Pioneer Moolec Science Produces Iron-Rich Beef Protein in Pea Seeds
Moolec Science, a Nasdaq‑listed molecular‑farming pioneer, announced the stable expression of bovine myoglobin—a heme‑rich, iron‑dense protein—in genetically engineered pea seeds, branded as PEEA1. The breakthrough, achieved after a 28‑month research partnership with a leading U.S. university, marks the first time...
Novel Phage Effectively Inhibits Antimicrobial-Resistant Salmonella, Biofilms on Food, Surfaces
Researchers at Gansu Agricultural University have identified a novel lytic bacteriophage, W5, that effectively targets antimicrobial‑resistant Salmonella across multiple food matrices. The phage remains stable at temperatures up to 50 °C and across a pH range of 3‑13, achieving 98% host...
AllRock Bio Begins Patient Dosing in Phase IIa ROCSTAR Trial
AllRock Bio has begun dosing the first patients in its Phase IIa ROCSTAR trial of ROC‑101, an oral pan‑ROCK inhibitor aimed at pulmonary hypertension. The multi‑center study will enroll up to 30 pulmonary arterial hypertension (PAH) patients and 10 interstitial lung...
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development is shifting toward precision immunotherapies, with biomarkers driving patient selection and trial efficiency. Experts at a Caidya webinar highlighted two trends: novel combination regimens and early integration of biomarker strategies, including companion diagnostics. Early biomarker adoption can...
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
Revolution Medicines’ daraxonrasib (RMC‑6236) was crowned 2025 Molecule of the Year after winning 50% of community votes. The oral, tri‑complex molecular glue inhibitor uniquely targets the active GTP‑bound state of KRAS, NRAS and HRAS, covering both mutant and wild‑type isoforms....
Gan & Lee and JW Pharmaceutical Agree on Bofanglutide Commercialisation
Gan & Lee Pharmaceuticals has signed an exclusive licence with JW Pharmaceutical to develop and commercialise the GLP‑1RA bofonaglutide in South Korea. JW will receive a $5 million upfront payment and up to $76.1 million in milestones, bringing total potential value to...
FDA Approves Higher Dose Nusinersen for Spinal Muscular Atrophy
The FDA has approved a higher‑dose regimen of nusinersen (Spinraza) for spinal muscular atrophy, updating both the loading and maintenance phases. The new schedule delivers two larger injections two weeks apart, followed by maintenance doses every four months. Approval follows...
Addressing Pain Points in Organoid Sorting: The Orgadroid
Visienco, a Swiss life‑sciences startup, unveiled the Orgadroid—an automated platform that combines precision robotics with AI‑driven microscopy to sort and classify organoids. The organoid market is forecast to reach $15.01 billion by 2031, growing at a 22.43% CAGR, but manual handling...
Telix Reports US FDA Acceptance of NDA for TLX101-Px (Pixclara) in Glioma Imaging
Telix Pharma announced that the U.S. FDA has accepted the resubmitted New Drug Application for TLX101‑Px, marketed as Pixclara, an investigational 18F‑FET PET imaging agent for glioma detection in adults and children. The agency set a PDUFA action date of...
Amgen’s Lung Cancer Drug Tarlatamab Wins China Approval
Amgen’s bispecific antibody tarlatamab, marketed in the U.S. as Imdelltra, has received approval from China’s National Medical Products Administration. The drug is designed for adults with extensive‑stage small cell lung cancer that has progressed despite chemotherapy. Amgen will commercialize the...
UK Cancer Trial Targets Difficult-to-Treat Tumours in Children
A new CAR T‑cell immunotherapy trial, called Mighty, will enroll up to 60 children and young adults with hard‑to‑treat solid tumours in the UK and US. The study targets rhabdomyosarcoma, Ewing sarcoma and soft‑tissue sarcoma, cancers that behave differently from...
Multi-Agent AI Delivers Reliable and Scalable Insights for Single-Cell Omics
Nygen Analytics, a Lund‑based startup founded by computational genomics expert Parashar Dhapola, is deploying multi‑agent AI to streamline single‑cell omics analysis. The platform automates cell‑type annotation, handling millions of cells while reducing error rates that can misguide drug discovery. By...
Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader
Gilead Sciences exercised its option to exclusively license KT‑200, a first‑in‑class oral CDK2 molecular‑glue degrader, from Kymera Therapeutics. The transaction triggers a $45 million milestone payment, with Kymera eligible for up to $750 million in additional milestones and tiered royalties. Gilead will...
Iron‐Based Metal‐Organic Framework MIL‐100(Fe) Regulates Keloid Scarring in a Humanized Keloid Model
The study shows iron‑based metal‑organic framework MIL‑100(Fe) nanoparticles are highly biocompatible, rapidly taken up by keloid fibroblasts, and selectively inhibit the TGF‑β/SMAD pathway, reducing collagen I, collagen III, and P4HA1 expression. In vitro experiments maintained >90% cell viability and curtailed...
Imagene AI Partners with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology
Imagene AI has teamed up with Daiichi Sankyo to use its OI Suite, powered by the CanvOI foundation model, for multimodal biomarker discovery in oncology. The collaboration will integrate H&E and IHC whole‑slide images with molecular and clinical data to...
Advanced Biotech Delivers Precise Disease Detection
Accurate Disease Detection with Advanced Biotech Diagnostics by @antgrasso #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/71nTNGOdDQ
Ambrosia AI Slashes Nutraceutical Ingredient Development From Years to Hours
Applied Laboratory Technologies unveiled Ambrosia, an AI‑driven platform that can compress the development of nutrition ingredients from multi‑year timelines to a matter of hours. Co‑founders Dr. Paul Spagnuolo and Brian Johnston say the system replicated five years of lab work...
Scala Biodesign Raises $16 Million Series A to Speed Protein Bio‑hacking
Scala Biodesign announced a $16 million Series A round led by Grove Ventures to expand its ScalaOS platform, which uses AI and physics‑based modeling to streamline protein engineering. The funding aims to cut years of trial‑and‑error for drugmakers developing longevity‑focused biologics.
Evotec Posts 7% Revenue Drop but Secures $650M Sandoz Deal and Phase II Pipeline Gains
Evotec SE posted third‑quarter 2025 revenue of €535.1 million, a 7% decline, while unveiling a strategic sale of its Just‑Evotec Biologics site to Sandoz valued at over $650 million. The company also highlighted cost‑out progress and the advancement of two drug candidates...
Louisiana Judge Upholds Lawsuit, Orders FDA to Complete Mifepristone Safety Review
U.S. District Judge David C. Joseph in Lafayette upheld Louisiana’s lawsuit against the FDA, ordering the agency to finish its safety review of the abortion pill mifepristone within six months. The decision leaves the drug’s mail‑order availability intact for now...
Joint‑On‑Chip Platforms Add Real‑Time Multi‑Sensor Capabilities for Disease Monitoring
A team led by Paola Occhetta has integrated multi‑modal sensors into joint‑on‑chip (JoC) platforms, moving the technology from endpoint assays to continuous, nondestructive monitoring of joint disease. The breakthrough promises faster drug testing and more precise, personalized treatments for osteoarthritis...
STAAR Surgical Posts 111% Q1 Revenue Surge, Shares Jump 23%
STAAR Surgical announced preliminary first‑quarter net sales of more than $90 million, a 111% increase over the same period a year earlier. The surge lifted the stock 23% in pre‑market trading and 19.25% in after‑hours, underscoring rapid market adoption of its...
Ossium Health Hosts Facility Tour and Reception for Indiana Governor Mike Braun and Healthcare Leaders
Ossium Health hosted a facility tour and reception with Indiana Governor Mike Braun, showcasing its 34,000‑square‑foot Indianapolis plant that houses five ISO 7 cleanrooms and a bone‑marrow banking platform. The company has treated 23 patients using organ donor‑derived bone marrow, underscoring...
Egypt Launches Largest Whole‑Genome Sequencing Project to Power Precision Medicine
Egypt announced the launch of its biggest whole‑genome sequencing effort, analyzing 1,024 volunteers from 21 governorates and identifying roughly 17 million previously unknown variants. The initiative creates the country’s first comprehensive genomic reference, a cornerstone for precision medicine and genetics‑based biohacking.
University of Michigan Nanoparticle Blocks Tick‑Borne Red‑Meat Allergy in Mice
University of Michigan scientists have demonstrated that an intravenously delivered nanoparticle can prevent the allergic response to red meat caused by lone‑star tick bites in mice, with 10 of 12 test subjects showing a muted immune reaction. The finding could...
Analysis of Rare Coding Variants in Schizophrenia-Associated Genes and Generalised Cognition in the UK Biobank
The study examined whole‑exome data from 396,848 UK Biobank participants to test whether rare damaging coding variants in schizophrenia‑linked genes affect generalised cognitive ability (g) in individuals without psychiatric diagnoses. Rare protein‑truncating variants (PTVs) and deleterious missense mutations in loss‑of‑function...
Vedanta Biosciences Showcases Innovative Work on Its Microbiome-Based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)...
Vedanta Biosciences presented a poster on its eight‑strain consortium VE303 and an oral talk on VE707 at the ESCMID 2026 Congress in Munich. VE303 showed more than an 80% reduction in recurrent Clostridioides difficile infection odds in a Phase 2 trial...
AI-Designed Proteins Built From Scratch Can Recognize Specific Compounds
Researchers at KAIST, led by Gyu Rie Lee and David Baker, used an AI model to design artificial proteins from scratch that selectively bind specific compounds. The team experimentally validated six de novo binding proteins, including a cortisol‑responsive biosensor that functions as a chemical‑induced...